New insights into the pharmacodynamic and pharmacokinetic properties of statins

Pharmacology and Therapeutics

Volumn 84, Issue 3, 1999, Pages 413-428

  Corsini, Alberto ^a   Bellosta, Stefano ^a   Baetta, Roberta ^a   Fumagalli, Remo ^a   Paoletti, Rodolfo ^a   Bernini, Franco ^b  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF PARMA   (Italy)

Author keywords

HMG CoA reductase inhibitors; Pharmacodynamics; Pharmacokinetics; Statins

Indexed keywords

ATORVASTATIN; CERIVASTATIN; CYCLOSPORIN A; CYTOCHROME P450; DIGOXIN; ERYTHROMYCIN; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; MEVINOLIN; MIBEFRADIL; NEFAZODONE; NICOTINIC ACID; PRAVASTATIN; SIMVASTATIN; STATINE DERIVATIVE; WARFARIN;

ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; DRUG METABOLISM; HUMAN; HYPERCHOLESTEROLEMIA; MYOSITIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; RHABDOMYOLYSIS;

ANIMALS; ANTICHOLESTEREMIC AGENTS; CELL DIVISION; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; FATTY ACIDS, MONOUNSATURATED; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INDOLES; MEVALONIC ACID; PYRIDINES; PYRROLES; SIMVASTATIN;

EID: 0032805692     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0163-7258(99)00045-5     Document Type: Review

References (182)

1. Ahmad S. Lovastatin. warfarin interaction Arch Intern Med. 150:1990;2407.
2. Aker S., Ivens K., Guo Z., Grabensee B., Heering P. Cardiovascular complications after renal transplantation. Transplant Proc. 30:1998;2039-2042.
3. Aminou P.N., van Vliet A.K., van Erck M., van Thiel G.C.F., van Leeuwen R.E.W., Cohen L.H. Inhibition of proliferation of human smooth muscle cells by various HMG-CoA reductase inhibitors; comparison with other human cell types. Biochim Biophys Acta. 1345:1997;259-268.
4. Anon FDA announce new drug-interaction warnings for mibefradil. Am J Health Syst Pharm. 55:1998;210.
5. Appel S., Dingemanse J. Clinical pharmacokinetics of fluvastatin with reference to other HMG-CoA reductase inhibitors. Drugs Today. 32:1996;39-55.
6. Arnadottir M., Eriksson L.-O., Thysell H., Karkas J.D. Plasma concentration profiles of simvastatin 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitory activity in kidney transplant recipients with and without ciclosporin. Nephron. 65:1993;410-413.
7. Arnadottir M., Eriksson L.-O., Germershausen J.I., Thysell H. Low-dose simvastatin is a well tolerated and efficacious cholesterol-lowering agent in ciclosporin-treated kidney transplant recipients. double-blind, randomized, placebo-controlled study in 40 patients Nephron. 68:1994;57-62.
8. Aviram M., Dankner G., Cogan U., Hochgraf E., Brook J.G. Lovastatin inhibits low-density lipoprotein oxidation and alters its fluidity and uptake by macrophages. in vitro and in vivo studies Metabolism. 41:1992;229-235.
9. Ayanian J.Z., Fuchs C.S., Stone R.M. Lovastatin and rhabdomyolisis. Ann Intern Med. 109:1988;682-683.
10. Baetta R., Donetti E., Comparato C., Calore M., Rossi A., Teruzzi C., Paoletti R., Fumagalli R., Soma M.R. In vitro and in vivo apoptosis by atorvastatin in stimulated smooth muscle cells. Pharmacol Res. 36:1997;115-121. a.
11. Baetta R., Paoletti R., Fumagalli R., Soma M.R. Mevalonate modulation of cell proliferation and apoptosis. Oncol Rep. 4:1997;257-261. b.
12. Bandoh T., Mitani H., Niihashi M., Bandoh T., Mitani H., Niihashi M., Kusumi Y., Ishikawa J., Kimura M., Totsuka T., Sakurai I., Hayashi S. Inhibitory effect of fluvastatin at doses insufficient to lower serum lipids on the catheter-induced thickening of intima in rabbit femoral artery. Eur J Pharmacol. 315:1996;37-42.
13. Bays H.E., Dujovne C.A. Drug interactions of lipid-altering drugs. Drug Safety. 19:1998;355-371.
14. Bellosta S., Bernini F., Ferri N., Quarato P., Canavesi M., Arnaboldi L., Fumagalli R., Paoletti R., Corsini A. Direct vascular effects of HMG-CoA reductase inhibitors. Atherosclerosis. 137(suppl.):1998;S101-S109. a.
15. Bellosta S., Via D., Canavesi M., Pfister P., Fumagalli R., Paoletti R., Bernini F. HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages. Arterioscler Thromb Vasc Biol. 18:1998;1671-1678. b.
16. Bernini F., Didoni G., Bonfadini G., Bellosta S., Fumagalli R. Requirement for mevalonate in acetylated LDL induction of cholesterol esterification in macrophages. Atherosclerosis. 104:1993;19-26.
17. Bernini F., Scurati N., Bonfadini G., Fumagalli R. HMG-CoA reductase inhibitors reduce acetyl LDL endocytosis in mouse peritoneal macrophages. Arterioscler Thromb Vasc Biol. 15:1995;1352-1358.
18. Bertz R.J., Granneman G.R. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin Pharmacokinet. 32:1997;210-258.
19. Bocan T.M.A., Mazur M.J., Mueller S.B., Brown E.Q., Sliskovic D.R., O'Brien P.M., Creswell M.W., Lee H., Uhlendorf P.D., Roth B.D. Antiatherosclerotic activity of inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase in cholesterol-fed rabbits. a biochemical and morphological evaluation Atherosclerosis. 111:1994;127-142.
20. Bochaton Piallant M.L., Gabbiani F., Redard M., Desmoulière A., Gabbiani G. Apoptosis participates in cellularity regulation during rat aortic intimal thickening. Am J Pathol. 146:1995;1059-1064.
21. Bourcier T., Aikawa M., Libby P. The HMG-CoA reductase inhibitors atorvastatin and lovastatin reduce accumulation of collagenase and 92-kD gelatinase released by cultured human monocytic and vascular smooth muscle cells. Atherosclerosis. 134:1997;121.
22. Braun W.E., Marwick T.H. Coronary artery disease in renal transplant recipients. Cleve Clin J Med. 61:1994;370-385.
23. Brouwer, K. L. R., Dukes, G. E., & Powell, J. R. (1994). Influence of liver function on drug disposition. In W. E. Evans, J. J. Schentag, & W. J. Jusko (Eds.), Applied Pharmacokinetics: Principles of Therapeutic Drug Monitoring, 3rd Ed., Ch. 6 (pp. 6-1-6-59). Vancouver: Applied Therapeutics.
24. Brown B.G., Zhao X.-Q., Sacco D.E., Albers J.J. Lipid lowering and plaque regression. new insights into prevention of plaque disruption and clinical events in coronary disease Circulation. 87:1993;1781-1791.
25. Brown M.S., Goldstein J.L. Drugs used in the treatment of hyperlipoproteinemias. Gilman A.G., Rall T.W., Nies A.L., Taylor P. The Pharmacological Basis of Therapeutics. 1991;874-896 Pergamon Press, Oxford.
26. Buchwald H., Varco R.L., Matts J.P., Long J.M., Fitch L.L., Campbell G.S., Pearce M.B., Yellin A.E., Edmiston W.A., Smik R.D. Jr. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH). N Engl J Med. 323:1990;946-955.
27. Cheng H., Rogers J.D., Sweany A.E., Dobrinska M.R., Stein E.A., Tate A.C., Amin R.D., Quan H. Influence of age and gender on the plasma profiles of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitory activity following multiple doses of lovastatin and simvastatin. Pharm Res. 9:1992;1629-1634.
28. Christians U., Jacobsen W., Floren L.C. Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in transplant patients. are the statins mechanistically similar? Pharmacol Ther. 80:1998;1-34.
29. Cignarella A., Brennhausen B., von Eckardstein A., Assmann G., Cullen P. Differential effects of lovastatin on the trafficking of endogenous and lipoprotein-derived cholesterol in human monocyte-derived macrophages. Arterioscler Thromb Vasc Biol. 18:1998;1322-1329.
30. Cilla D.D., Whitfield L.R., Gibson D.M., Sedman A.J., Posvar E.L. Multiple-dose pharmacokinetics, pharmacodynamics, and safety of atorvastatin, an inhibitor of HMG-CoA reductase, in healthy subjects. Clin Pharmacol Ther. 60:1996;687-695.
31. Colli S., Eligini S., Lalli M., Camera M., Paoletti R., Tremoli E. Vastatins inhibit tissue factor in cultured human macrophages. A novel mechanism of protection against atherothrombosis. Arterioscler Thromb Vasc Biol. 17:1997;265-272.
32. Combalbert J., Fabre I., Fabre G., Daleti I., Delacourt J., Cano J.P., Maurel P. Metabolism and cyclosporine A. IV. Purification and identification of the rifampicin inducible human liver cytochrome P-450 (cyclosporine A oxidase) as a product of P450IIIA gene subfamily. Drug Metab Dispos. 17:1989;197-207.
33. Corpier C.L., Jones P.H., Suki W.N., Lederer E.D., Quinones M.A., Schmidt S.W., Young J.B. Rhabdomyolysis and renal injury with lovastatin use. Report of two cases in cardiac transplant recipients. JAMA. 260:1988;239-241.
34. Corsini A., Mazzotti M., Raiteri M., Soma M.R., Gabbiani G., Fumagalli R., Paoletti R. Relationship between mevalonate pathway and arterial myocyte proliferation. in vitro studies with inhibitors of HMG-CoA reductase Atherosclerosis. 101:1993;117-125.
35. Corsini A., Maggi F.M., Catapano A.L. Pharmacology of competitive inhibitors of HMG-CoA reductase. Pharmacol Res. 31:1995;9-27.
36. Corsini A., Bernini F., Quarato P., Donetti E., Bellosta S., Fumagalli R., Paoletti R., Soma M.R. Non-lipid-related effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Cardiology. 87:1996;458-468. a.
37. Corsini A., Pazzucconi F., Pfister P., Paoletti R., Sirtori C.R. Inhibitor of proliferation of arterial smooth-muscle cells by fluvastatin. Lancet. 348:1996;1584. b.
38. Corsini A., Pazzucconi F., Arnaboldi L., Pfister P., Fumagalli R., Paoletti R., Sirtori C. Direct effects of statins on the vascular wall. J Cardiovasc Pharmacol. 31:1998;773-778.
39. Dain J.G., Fu E., Gorski J., Nicoletti J., Scallen T.J. Biotransformation of fluvastatin sodium in humans. Drug Metab Dispos. 21:1993;567-572.
40. De Angelis D.A., Braun P.E. Binding of 2′,3′-cyclic nucleotide 3′-phosphodiesterase to myelin. an in vitro study J Neurochem. 66:1996;2523-2531.
41. Desager J.P., Horsmans Y. Clinical pharmacokinetics of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. Clin Pharmacokinet. 31:1996;348-371.
42. De Smedt F., Boom A., Pesesse X., Schiffmann N., Erneux C. Post-translational modification of human brain type I inositol-1,4,5-trisphosphate 5-phosphatase by farnesylation. J Biol Chem. 271:1996;10419-10424.
43. Dollery C.M., McEvan J.R., Henney A.M. Matrix metalloproteinases and cardiovascular disease. Circ Res. 77:1995;863-868.
44. Downs J.R., Clearfield M., Weis S., Whitney E., Shapiro D.R., Beere P.A., Langendorfer A., Stein E.A., Kruyer W., Gotto A.M. Jr. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. results of AFCAPS/TexCAPS JAMA. 279:1998;1615-1622.
45. Duell P.B., Connor W.E., Illingworth D.R. Rhabdomyolysis after taking atorvastatin with gemfibrozil. Am J Cardiol. 81:1998;368-369.
46. Duggan D.E., Vickers S. Physiological disposition of HMG-CoA reductase inhibitors. Drug Metab Rev. 22:1990;333-362.
47. Dujovne C.A., Chremos A.N., Pool J.L., Schnaper H., Bradford R.H., Shear C.L., Higgins J., Downton M., Franklin F.A., Nash D.T. Expanded clinical evaluation of lovastatin (EXCEL) study results. IV. Additional perspectives on the tolerability of lovastatin. Am J Med. 91(suppl. 1B):1991;25S-30S.
48. East C., Alivizatos P.A., Grundy S.M., Jones P.H., Farmer J.A. Rhabdomyolysis in patients receiving lovastatin after cardiac transplantation. N Engl J Med. 318:1988;47-48.
49. Endo A. The discovery and development of HMG-CoA reductase inhibitors. J Lipid Res. 33:1992;1569-1582.
50. Endres M., Laufs U., Huang Z., Nakamura T., Huang P., Moskowitz M.A., Liao J.K. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci USA. 95:1998;8880-8885.
51. Ernst M.E., Kelly M.W. Mibefradil, a pharmacologically distinct calcium antagonist. Pharmacotherapy. 18:1998;463-485.
52. Essig M., Nguyen G., Pri D., Escoubet B., Sraer J.D., Friedlander G. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors increase fibrinolytic activity in rat aortic endothelial cells. Circ Res. 83:1998;683-690.
53. Falk E., Shah P.K., Fuster V. Coronary plaque disruption. Circulation. 92:1995;657-671.
54. Feussner G. HMG-CoA reductase inhibitors. Curr Opin Lipidol. 5:1994;59-68.
55. Fischer V., Johanson L., Heitz F., Tullman R., Graham E., Baldeck J.-P., Robinson W.T. The HMG-CoA reductase inhibitor fluvastatin. effect on human cytochrome P450 and implications for metabolic drug interactions Drug Metab Dispos. 27:1999;410-416.
56. Garnett W.R. Interactions with hydroxymethylglutaryl-coenzyme A reductase inhibitors. Am J Health Syst Pharm. 52:1995;1639-1645.
57. Garnett W.R., Venitz J., Wilkens R.C., Dimenna G. Pharmacokinetic effects of fluvastatin in patients chronically receiving digoxin. Am J Med. 96A:1994;84S-86S.
58. Gaw A., Wosornu D. Simvastatin during warfarin therapy in hyperlipoproteinaemia. Lancet. 340:1992;979-980.
59. Gellman J., Ezekowitz M.D., Sarembock I.J., Azrin M.A., Nochomowitz L.E., Lerner E., Haudenschild C.C. Effect of lovastatin on intimal hyperplasia after balloon angioplasty. A study in an atherosclerotic hypercholesterolemic rabbit. J Am Coll Cardiol. 17:1991;251-259.
60. Gibaldi, M. (1991). Pharmacokinetic variability-drug interactions. In M. Gibaldi (Ed.), Biopharmaceutics and Clinical Pharmacokinetics, 4th Ed. (pp. 305-343). Philadelphia: Lea & Febiger.
61. Giroux L.M., Davignon J., Naruzewicz M. Simvastatin inhibits the oxidation of low-density lipoproteins by activated human monocyte-derived macrophages. Biochim Biophys Acta. 1165:1993;335-338.
62. Glomset J.A., Gelb M.H., Farnsworth C.C. Prenyl proteins in eukaryotic cells. a new type of membrane anchor Trends Biochem Sci. 15:1990;139-142.
63. Goldberg R., Roth D. Evaluation of fluvastatin in the treatment of hypercholesterolemia in renal transplant recipients taking cyclosporine A. Transplantation. 62:1996;1559-1564.
64. Goldstein J.L., Brown M.S. Regulation of the mevalonate pathway. Nature. 343:1990;425-430.
65. Gonzalez J.M., Badimon L. Human and porcine smooth muscle cells share similar proliferation dependence on the mevalonate pathway. Implication for in vivo interventions in the porcine model Eur J Clin Invest. 26:1996;1023-1032.
66. Gonzalez J.M., Vinals M., Vidal F., Llorente-Corts V., Badimon L. Mevalonate deprivation impairs IGF-I/insulin signaling in human vascular smooth muscle cells. Atherosclerosis. 135:1997;213-223.
67. Grunler J., Ericsson J., Dallner G. Branch-point reactions in the biosynthesis of cholesterol, dolichol, ubiquinone and prenylated proteins. Biochim Biophys Acta. 1212:1994;259-277.
68. Guijarro C., Blanco-Colio L.M., Ortego M., Alonso C., Ortiz A., Plaza J.J., Diaz C., Ernandez G., Egido J. 3-Hydroxy-3-methylglutaryl coenzyme A reductase and isoprenylation inhibitors induce apoptosis of vascular smooth muscle cells in culture. Circ Res. 83:1998;490-500.
69. Halstenson C.E., Triscari J., De Vault A., Shapiro B., Keane W., Pan H. Single-dose pharmacokinetics of pravastatin and metabolites in patients with renal impairment. J Clin Pharmacol. 32:1992;124-132.
70. Hamelin B.A., Turgeon J. Hydrophilicity/lipophilicity. relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors Trends Pharmacol Sci. 19:1998;26-37.
71. Han D.K.M., Haudenschild C.C., Hong M.K., Tinkle B.T., Leon M.B., Liau G. Evidence for apoptosis in human atherogenesis and in rat vascular injury model. Am J Pathol. 147:1995;267-277.
72. Haria M., McTavish D. Pravastatin. A reappraisal of its pharmacological properties and clinical effectiveness in the management of coronary heart disease. Drugs. 53:1997;299-336.
73. Havel R.J., Rapaport E. Management of primary hyperlipidemia. N Engl J Med. 332:1995;1301-1307.
74. Henwood J.M., Heel R.C. Lovastatin. A preliminary review of its pharmacodynamic properties and therapeutic use in hyperlipidaemia. Drugs. 31:1995;9-27.
75. Herd J.A., Ballantyne C.M., Farmer J.A., Ferguson J.J. III, Jones P.H., West M.S., Gould K.L. Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS]). Am J Cardiol. 80:1997;278-286.
76. Hernandez-Perera O., Perez-Sala D., Navarro-Antolin J., Sanchez-Pascuala R., Hernandez G., Diaz C., Lamas S. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest. 101:1998;2711-2719.
77. Hirsh J. Oral anticoagulant drugs. N Engl J Med. 324:1991;1865-1875.
78. Hoffman H.S. The interaction of lovastatin and warfarin. Conn Med. 56:1992;107.
79. Holdaas H., Hartmann A., Stenstrom J., Dahl K., Borge M., Pfister P. Effect of fluvastatin for safely lowering atherogenic lipids in renal transplant patients receiving cyclosporine A. Am J Cardiol. 76:1995;102A-106A.
80. Holdaas, H., Fellström, B., & Holme, I. for the ALERT Study Group (1998). The ALERT trial: rationale and baseline data. In Abstracts of the XVII World Congress of the Transplantation Society, Montreal, July 12-17.
81. Horl W.H., Riegel W., Wanner C., Haag-Weber M., Schollmeyer P., Wieland H., Wilms H. Endocrine and metabolic abnormalities following kidney transplantation. Klin Wochenschr. 67:1989;907-918.
82. Hsu I., Spiler S.A., Johnson N.E. Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia. Ann Pharmacother. 29:1995;743-759.
83. Hunninghake D.B. HMG-CoA reductase inhibitors. Curr Opin Lipidol. 3:1992;22-28.
84. Hussein O., Schlezinger S., Rosenblat M., Keidar S., Aviram M. Reduced susceptibility of low density lipoprotein (LDL) to lipid peroxidation after fluvastatin therapy in associated with the hypocholesterolemic effect of the drug and its binding to the LDL. Atherosclerosis. 128:1997;11-18.
85. Igarashi M., Takeda Y., Mori S., Ishibashi N., Komatsu E., Takahashi K., Fuse T., Yamamura M., Kubo K., Sugiyama Y., Saito Y. Suppression of neointimal thickening by a newly developed HMG-CoA reductase inhibitor, BAYW6228 and its inhibitory effect on vascular smooth muscle cell growth. Br J Pharmacol. 120:1997;1172-1178.
86. Inglese J., Koch W.J., Touhara K., Lefkowitz R.J. Gβγ interaction with PH domains and Ras-MPK signaling pathways. Trends Biochem Sci. 20:1995;151-156.
87. Isner J.M., Kearney M., Boartman S., Passeri J. Apoptosis in human atherosclerosis and restenosis. Circulation. 91:1995;2703-2711.
88. Jacobson R.H., Wang P., Glueck C.J. Myositis and rhabdomyolisis associated with concurrent use of simvastatin and nefazodone. JAMA. 277:1997;296.
89. Jokubaitis L.A. Updated clinical safety experience with fluvastatin. Am J Cardiol. 73:1994;18D-24D.
90. Jones K.J., Couldwell W.T., Hinton D.R., Su Y., He S., Anker L., Law R.E. Lovastatin induces growth inhibition and apoptosis in human malignant glioma cells. Biochem Biophys Res Commun. 205:1994;1681-1687.
91. Jukema J.W., Bruschke A.V.G., van Boven A.J., Reiber J.H., Bal E.T., Zwinderman A.H., Jansen H., Boerma G.J., van Rappard F.M., Lie K.I. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS) Circulation. 91:1995;2528-2540.
92. Kaesemeyer W.H. Pravastatin sodium activates endothelial nitric oxide synthase independently of its cholesterol-lowering actions. J Am Coll Cardiol. 33:1999;234-241.
93. Kandus A., Kovac D., Cerne D., Koselj M., Kaplan-Pavlovcic S., Buturovic J., Ponikvar R., Kveder R., Lindic J., Bren A.F. Therapy of hyperlipidemia with lovastatin in kidney transplant patients on cyclosporine A immunosuppression. three-year experience Transplant Proc. 30:1998;1307-1309.
94. Kantola T., Kivistö K.T., Neuvonen P.J. Pharmacokinetics and drug disposition. Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid. Clin Pharmacol Ther. 63:1998;397-402. a.
95. Kantola T., Kivistö K.T., Neuvonen P.J. Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations. Clin Pharmacol Ther. 64:1998;177-182. b.
96. Kasiske B.L., Umen A.J. Persistent hyperlipidemia in renal transplant patients. Medicine. 66:1987;309-316.
97. Kitazawa E., Tamura N., Iwabuchi H., Uchiyama M., Muramatsu S., Takahagi H., Tanaka M. Biotransformation of pravastatin sodium. Biochem Biophys Res Commun. 192:1993;597-602.
98. Kivistö K.T., Kantola T., Neuvonen P.J. Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin. Br J Clin Pharmacol. 46:1998;49-53.
99. Kjekshus J., Pedersen T.R., Tobert J.A. Lipid-lowering therapy for patients with or at risk of coronary artery disease. Curr Opin Lipidol. 11:1996;418-427.
100. Kline S.S., Harrell C.C. Potential warfarin-fluvastatin interaction. Ann Pharmacother. 31:1997;790.
101. Klintmalm G.B.G., Iwatsuki S., Starzl T.E. Cyclosporine A hepatotoxicity in 66 renal allograft recipients. Transplantation. 32:1981;488-489.
102. Kockx M.M., Cambier B.A., Bortier H.E., De Meyer G.R., Declercq S.C., Van Cauwelaert P.A., Bultick J. Foam cell replication and smooth muscle cell apoptosis in human saphenous vein grafts. Histopathology. 25:1994;365-371.
103. Laufs U., La Fata V., Liao J.K. Inhibition of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase blocks hypoxia-mediated down-regulation of endothelial nitric oxide synthase. J Biol Chem. 272:1997;31725-31729.
104. Laufs U., La Fata V., Plutzky J., Liao J.K. Upregulation of endothelial nitric oxide synthase by HMG-CoA reductase inhibitors. Circulation. 97:1998;1129-1135.
105. La Ville A., Moshy R., Turner P.R., Miller N.E., Lewis B. Inhibition of cholesterol synthesis reduces low-density-lipoprotein apoprotein B production without decreasing very-low-density-lipoprotein apoprotein B synthesis in rabbits. Biochem J. 218:1984;321-323.
106. Laxminarayan K.M., Chan B.K., Tetaz T., Bird P.I., Mitchell C.A. Characterization of a cDNA encoding the 43-kDa membrane-associated inositol-polyphosphate 5-phosphatase. J Biol Chem. 269:1994;17305-17310.
107. Lees R.S., Lees A.M. Rhabdomyolysis from the coadministration of lovastatin and the antifungal agent itraconazole. N Engl J Med. 333:1995;664-665.
108. Lennernas H., Fager G. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Clin Pharmacokinet. 32:1997;403-425.
109. Liao J.K., Zulueta J.J., Feng-Sheng Y., Peng H., Cote C.G., Hassoun P.M. Regulation of bovine endothelial constitutive nitric oxide synthase by oxygen. J Clin Invest. 96:1995;2661-2666.
110. London S.F., Gross K.F., Ringel S.P. Cholesterol lowering agent myopathy. Neurology. 41:1991;1159-1160.
111. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 339(LIPIDStudyGroup()):1998;1349-1357.
112. Mai I., Bauer S., Fritsche J. Clinical pharmacokinetics of a new HMG-CoA reductase inhibitor in renal transplant patients treated with cyclosporin A (CSA). Eur J Clin Pharmacol. 52(suppl.):1997;A137.
113. Maltese W.A. Post-translational modification of proteins by isoprenoids in mammalian cells. FASEB J. 4:1990;3319-3328.
114. Masaaki K., Kurose I., Russell J., Granger D.N. Effect of fluvastatin on leukocyte-endothelial cell adhesion in hypercholesterolemic rats. Arterioscler Thromb Vasc Biol. 17:1997;1521-1526.
115. McClellan K.J., Wiseman L.R., McTavish D. Cerivastatin. Drugs. 55:1998;415-420.
116. Miller D.B., Spence J.D. Clinical pharmacokinetics of fibric acid derivatives (fibrates). Clin Pharmacokinet. 34:1998;155-162.
117. Mück W., Ritter W., Dietrich H., Frey R., Kuhlmann J. Influence of the antacid Maalox and the H2-antagonist cimetidine on the pharmacokinetics of cerivastatin. Int J Clin Pharmacol Ther. 35:1997;261-264. a.
118. Mück W., Ritter W., Frey R., Wetzelsberger N., Lucker P.W., Kuhlmann J. Influence of cholestyramine on the pharmacokinetics of cerivastatin. Int J Clin Pharmacol Ther. 35:1997;250-254. b.
119. Mück W., Ritter W., Ochmann K., Unger S., Ahr G., Wingender W., Kuhlmann J. Absolute and relative bioavailability of the HMG-CoA reductase inhibitor cerivastatin. Int J Clin Pharmacol Ther. 35:1997;255-260. c.
120. Mück W. Rational assessment of the interaction profile of cerivastatin supports its low propensity for drug interactions. Drugs. 56(suppl. 1):1998;15-23.
121. Mück W., Ochmann K., Mazzu A., Lettieri J. Biopharmaceutical profile of cerivastatin. a novel HMG-CoA reductase inhibitor Int J Med Res. 27:1999;107-114.
122. Munro E., Patel M., Chan P., Betteridge L., Clunn G., Gallagher K., Hughes A., Schachter M., Wolfe J., Sever P. Inhibition of human vascular smooth muscle cell proliferation by lovastatin. the role of isoprenoid intermediates of cholesterol synthesis Eur J Clin Invest. 24:1994;766-772.
123. Neuvonen P.J., Kantola T., Kivistö K.T. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clin Pharmacol Ther. 63:1998;332-334.
124. Nordin C., Dahl M.L., Eriksson M., Sjoberg S. Is the cholesterol-lowering effect of simvastatin influenced by CYP2D6 polymorphism? Lancet. 350:1997;29-30.
125. Norman D.J., Illingworth D.R., Munson J., Hosenpud J. Myolysis and acute renal failure in heart-transplant patient receiving lovastatin. N Engl J Med. 318:1988;46-47.
126. O'Driscoll G., Green D., Taylor R.R. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation. 95:1997;1126-1131.
127. Olbricht C., Wanner C., Eisenhauer T., Kliem V., Doll R., Boddaert M., O'Grady P., Krekler M., Mangold B., Christians U. Accumulation of lovastatin, but not pravastatin, in the blood of cyclosporine A-treated kidney graft patients after multiple doses. Clin Pharmacol Ther. 62:1997;311-321.
128. Ong-Ajyooth L., Ong-Ajyooth S., Sirisalee K., Nilwarangkur S. Lipoproteins and lipid peroxidation abnormalities in patients with chronic renal disease. J Med Assoc Thai. 79:1996;505-512.
129. Packard C.J., West of Scotland Coronary Prevention Study Group Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation. 97:1998;1440-1445.
130. Pan H.Y., DeVault A.R., Swites B.J., Whigan D., Ivashkiv E., Willard D.A., Brescia D. Pharmacokinetics and pharmacodynamics of pravastatin alone and with cholestyramine in hypercholesterolemia. Clin Pharmacol Ther. 48:1990;201-207.
131. Pan H.Y., Triscar J., Devault A.R., Smith S.A., Wangiverson D., Swanson B.N., Willard D.A. Pharmacokinetic interaction between propranolol and the HMG-CoA reductase inhibitors pravastatin and lovastatin. Br J Clin Pharmacol. 31:1991;665-670.
132. Perez-Sala D., Mollinedo F. Inhibition of isoprenoid biosynthesis induces apoptosis in human promyelocytic HL-60 cells. Biochem Biophys Res Commun. 199:1994;1209-1215.
133. Perez-Sala D., Collado-Escobar D., Mollinedo F. Intracellular alkalination suppresses lovastatin-induced apoptosis in HL-60 cells through the inactivation of a pH-dependent indonuclease. J Biol Chem. 270:1995;6235-6242.
134. Peters T.K., Jewitt-Harris J., Mehra M., Muratti E.N. Safety and tolerability of fluvastatin with concomitant use of antihypertensive agents. An analysis of a clinical trial database. Am J Hypertens. 6:1993;346S-352S.
135. Pierce L.R., Wysowski D.K., Gross T.P. Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy. JAMA. 264:1990;71-75.
136. Pogson G.W., Kindred L.H., Carper G.C. Rhabdomyolysis and renal failure associated with cerivastatin-gemfibrozil combination therapy. Am J Cardiol. 83:1999;1146.
137. Posvar E.L., Radulovic L.L., Cilla D.D., Whitfield L.R., Sedman A.J. Tolerance and pharmacokinetics of single-dose atorvastatin, a potential inhibitor of HMG-CoA reductase, in healthy subjects. J Clin Pharmacol. 36:1996;728-731.
138. Quion J.A.V., Jones P.H. Clinical pharmacokinetics of pravastatin. Clin Pharmacokinet. 27:1994;94-103.
139. Raiteri M., Arnaboldi L., McGeady P., Gelb M.H., Verri D., Tagliabue C., Quarato P., Ferraboschi P., Santaniello E., Paoletti R., Fumagalli R., Corsini A. Pharmacological control of the mevalonate pathway. effect on arterial smooth muscle cell proliferation J Pharmacol Exp Ther. 281:1997;1144-1153.
140. Reaven P., Witztum J.L. Lovastatin, nicotinic acid, and rhabdomyolysis. Ann Intern Med. 109:1988;597-598.
141. Regazzi M.B., Iacona I., Campana C., Raddato V., Lesi C., Perani G., Gavazzi A., Vigano M. Altered disposition of pravastatin following concomitant drug therapy with cyclosporine A in transplant recipients. Transplant Proc. 25:1993;2732-2734.
142. Rettie A.E., Korzekwa K.R., Kunze K.L., Lawrence R.F., Eddy A.C., Aoyama T., Gelboin H.V., Gonzalez F.J., Trager W.F. Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450. A role for P-4502C9 in the etiology of (S)-warfarin-drug interactions Chem Res Toxicol. 5:1992;54-59.
143. Richter W.O., Jacob B.G., Schwandt P. Interaction between fibre and lovastatin. Lancet. 338:1991;706.
144. Riegger G., Abletshauser C., Ludwig M., Schwandt P., Widimsky J., Weidinger G., Welzel D. The effect of fluvastatin on cardiac events in patients with symptomatic coronary artery disease during one year of treatment. Atherosclerosis. 144:1999;263-270.
145. Rosenson R.S., Tangney C. Antiatherothrombotic properties of statins. JAMA. 279:1998;1643-1650.
146. Sacks F.M., Pfeffer M.A., Moye L.A., Rouleau J.L., Rutherford J.D., Cole T.G., Brown L., Warnica J.W., Arnold J.M., Wun C.C., Davis B.R., Braunwald E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 335:1996;1001-1009.
147. Sakai M., Kobori S., Matsumura T., Biwa T., Sato Y., Takemura T., Hakamata H., Horiuchi S., Shichiri M. HMG-CoA reductase inhibitors suppress macrophage growth induced by oxidized low density lipoprotein. Atherosclerosis. 133:1997;51-59.
148. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease. The Scandinavian Simvastatin Survival Study (4S) Lancet. 344:1994;1383-1389.
149. Schmassmann-Suhijar D., Bullingham R., Gasser R., Schmutz J., Haefeli W.E. Rhabdomyolysis due to interaction of simvastatin with mibefradil. Lancet. 351:1998;1929-1930.
150. Shepherd J. Fibrates and statins in the treatment of hyperlipidaemia. an appraisal of their efficacy and safety Eur Heart J. 16:1995;5-13.
151. Shepherd J., Cobbe S.M., Ford I., Isles C.G., Lorimer A.R., MacFarlane P.W., McKillop J.H., Packard C.J. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 333:1995;1301-1307.
152. Singhvi S.M., Pan H.Y., Morrison R.A., Willard D.A. Disposition of pravastatin sodium, a tissue-selective HMG-CoA reductase inhibitor, in healthy subjects. Br J Clin Pharmacol. 29:1990;239-243.
153. Smith H.T., Jokubaitis L.A., Troendle A.J., Hwang D.S., Robinson W.T. Pharmacokinetics of fluvastatin and specific drug interactions. Am J Hypertens. 6:1993;375S-382S.
154. Smith P.F., Eydelloth R.S., Grossman S.J., Stubbs R.J., Schwartz M.S., Germershausen J.I., Vyas K.P., Kari P.H., MacDonald J.S. HMG-CoA reductase inhibitor-induced myopathy in the rat. cyclosporine A interaction and mechanism studies J Pharmacol Exp Ther. 257:1991;1225-1235.
155. Soma M.R., Donetti E., Parolini C., Mazzini G., Ferrari C., Fumagalli R., Paoletti R. HMG-CoA reductase inhibitors. in vivo effects on carotid intimal thickening in normocholesterolemic rabbits Arterioscler Thromb Vasc Biol. 13:1993;571-578.
156. Soma M.R., Baetta R., De Renzis S., Mazzini G., Davegna C., Magrassi L., Butti G., Pezzotta S., Paoletti R., Fumagalli R. In vitro and in vivo enhanced anti-tumor activity of carmustine (BCNU) by simvastatin, a hypocholesterolemic drug. Cancer Res. 55:1995;597-602. a.
157. Soma M.R., Parolini C., Donetti E., Fumagalli R., Paoletti R. Inhibition of isoprenoid biosynthesis and arterial smooth muscle cell proliferation. J Cardiovasc Pharmacol. 25:1995;S20-S24. b.
158. Spach D.H., Bauwens J.E., Clark C.D., Burke W.G. Rhabdomyolysis associated with lovastatin and erythromycin use. West J Med. 154:1991;213-215.
159. Spence J.D., Munoz C.E., Hendicks L., Latchinian L., Khouri H.E. Pharmacokinetics of the combination of fluvastatin and gemfibrozil. Am J Cardiol. 76:1995;80A-83A.
160. Stern R., Abel R., Gibson G.L., Besserer J. Atorvastatin does not alter the anticoagulant activity of warfarin. J Clin Pharmacol. 37:1997;1062-1064.
161. Stern R.H., Gibson D.M., Whitfield L.R. Cimetidine does not alter atorvastatin pharmacokinetics or LDL-cholesterol reduction. Eur J Clin Pharmacol. 53:1998;475-478.
162. Stockley I.H. Drug Interactions. A Source Book of Adverse Interactions, Their Mechanisms, Clinical Importance and Management. 1996;Pharmaceutical Press, London.
163. Tal A., Rajeshawari M., Isley W. Rhabdomyolysis associated with simvastatin-genfibrozil therapy. South Med J. 90:1997;546-547.
164. Tapon N., Hall A. Rho Rac and Cdc42 GTPases regulate the organization of the actin cytoskeleton. Curr Opin Cell Biol. 9:1997;86-92.
165. Thummel K.E., Wilkinson G.R. In vitro and in vivo drug interaction involving human CYP3A. Annu Rev Pharmacol Toxicol. 38:1998;389-430.
166. Tobert J.A. Efficacy and long-term adverse effect pattern of lovastatin. Am J Cardiol. 62:1988;28J-34J.
167. Transon C., Leemann T., Vogt N., Dayer P. In vivo inhibition profile of cytochrome P450 tb (CYP2C9) by (±)-fluvastatin. Clin Pharmacol Ther. 58:1995;412-417.
168. Trilli L.E., Kelley C.L., Aspinall S.L., Kroner B.A. Potential interaction between warfarin and fluvastatin. Ann Pharmacother. 30:1996;1399-1402.
169. Tse F.L.S., Jaffe J.M., Troendle A. Pharmacokinetics of fluvastatin after single and multiple doses of normal volunteers. J Clin Pharmacol. 32:1992;630-638.
170. Tse F.L.S., Nickerson D.F., Yardley W.S. Binding of fluvastatin to blood cells and plasma proteins. J Pharm Sci. 82:1993;942-947.
171. Umetani N., Kanayama Y., Okamura M., Negoro N., Takeda T. Lovastatin inhibits gene expression of type-I scavenger receptor in THP-1 human macrophages. Biochim Biophys Acta. 1303:1996;199-206.
172. Vanhaecke J., Van Cleemput J., Van Lierde J., Daenen W., De Geest H. Safety and efficacy of low dose simvastatin in cardiac transplant recipients treated with cyclosporine A. Transplantation. 58:1994;42-45.
173. Wacher V.J., Wu C.Y., Benet L.Z. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein. implications for drug delivery and activity in cancer chemotherapy Mol Carcinogen. 13:1995;129-134.
174. Walker J.F. Simvastatin. the clinical profile Am J Med. 87(suppl. 4A):1989;44S-46S.
175. Wang R.W., Karl P.H., Lu A.Y.H., Thomas P.E., Guengerich F.P., Vyas K.P. Biotransformation of lovastatin. IV. Identification of cytochrome P450 3A proteins as the major enzymes responsible for the oxidative metabolism of lovastatin in rat and human liver microsomes. Arch Biochem Biophys. 290:1991;355-361.
176. Wilkinson G.R. Cytochrome P4503A (CYP3A) metabolism. prediction of in vivo activity in humans J Pharmacokinet Biopharm. 24:1996;475-489.
177. Williams J.K., Sukhova G.K., Herrington D.M., Libby P. Pravastatin has cholesterol-lowering independent effects on the artery wall of atherosclerotic monkeys. J Am Coll Cardiol. 31:1998;684-691.
178. Wrighton S.A., VandenBranden M., Ring B.J. The human drug metabolizing cytochromes P450. J Pharmacokinet Biopharm. 24:1996;461-473.
179. Yang B.B., Hounslow N.J., Sedman A.J., Forgue S.T. Effects of atorvastatin, an HMG-CoA reductase inhibitor, on hepatic oxidative metabolism of antipyrine. J Clin Pharmacol. 36:1996;356-360.
180. Yoshimura N., Oka T., Okamoto M., Ohmori Y. The effects of pravastatin on hyperlipidemia in renal transplant recipients. Transplantation. 53:1992;94-99.
181. Zhang F.L., Casey P.J. Protein prenylation. molecular mechanisms and functional consequences Annu Rev Biochem. 65:1996;241-269.
182. Zhu B.Q., Sievers R.E., Sun Y.P., Isenberg W.M., Parmley W.W. Effect of lovastatin on suppression and regression of atherosclerosis in lipid-fed rabbits. J Cardiovasc Pharmacol. 19:1992;246-255.